Bridge Bancorp, Inc. Announces Second Quarter 2017 Dividend
Jul 07, 2017 20:15 pm UTC| Business
BRIDGEHAMPTON, N.Y., July 07, 2017 -- Bridge Bancorp, Inc. (NASDAQ:BDGE), the holding company for The Bridgehampton National Bank, announced the declaration of a quarterly dividend of $0.23 per share. The dividend will...
Crown Castle Announces Second Quarter 2017 Earnings Release and Conference Call Schedule
Jul 07, 2017 20:15 pm UTC| Business
HOUSTON, July 07, 2017 -- Crown Castle International Corp. (NYSE:CCI) ("Crown Castle") announced today that it plans to release its second quarter 2017 results on Wednesday, July 19, 2017, after the market closes. In...
Firsthand Technology Value Fund Announces Postponement of Annual Stockholder Meeting
Jul 07, 2017 20:15 pm UTC| Business
SAN JOSE, Calif., July 07, 2017 -- Firsthand Technology Value Fund, Inc. (NASDAQ:SVVC) (the “Fund”), a publicly traded venture capital fund, announced today that it has postponed its 2017 Annual Meeting of Stockholders...
Jul 07, 2017 20:05 pm UTC| Business
GREENWICH, Conn. and DENVER, July 07, 2017 -- Conyers Park Acquisition Corp. (NASDAQ:CPAA) (“Conyers Park”), a publicly traded special purpose acquisition company, and an affiliate of Atkins Nutritionals, Inc....
Jul 07, 2017 20:05 pm UTC| Business
TUSTIN, Calif., July 07, 2017 -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology...
Chart Industries Announces Second Quarter 2017 Conference Call
Jul 07, 2017 20:05 pm UTC| Business
CLEVELAND, Ohio, July 07, 2017 -- Chart Industries, Inc. (NASDAQ:GTLS) has scheduled a conference call from its Georgia offices for Thursday, July 27, 2017, at 10:30 a.m. ET to discuss its second quarter 2017 financial...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 07, 2017 20:05 pm UTC| Business
BOSTON, July 07, 2017 -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today...